Loading...
Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre
Morrissey, Hana Ball, Patrick Ahmed, Ari Ibrahim, Rangeen Abadie, Mohammed
Morrissey, Hana
Ball, Patrick
Ahmed, Ari
Ibrahim, Rangeen
Abadie, Mohammed
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2019-04-28
Submitted date
Alternative
Abstract
A clinical pathway was created to feed information into a clinical audit checklist, and was adopted as the patient-management model for biological therapies. From this, the data was reviewed concerning 41 patients who were receiving SEC between January 2014 and December 2018. The results for the Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) score which are typically reviewed at baseline and at 16 weeks to assess response to treatment.
Citation
Abadie, M. et al. Continuation of therapy of secukinumab (SEC): Evidence from a tertiary referral centre, International Journal of Current Medical And Pharmaceutical Research, Vol. 5, Issue, 04(A), pp. 4114-4118, April, 2019
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en